NMDA receptor hypofunction model of schizophrenia.
暂无分享,去创建一个
J. Newcomer | J. Olney | N. Farber | J W Olney | J W Newcomer | N B Farber
[1] G. Ellison,et al. Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. , 1994, Neuroreport.
[2] E. Bullmore,et al. Society for Neuroscience Abstracts , 1997 .
[3] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .
[4] D. Cyril D’Souza,et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans , 1998, Psychopharmacology.
[5] Angus C Nairn,et al. The DARPP-32/protein phosphatase-1 cascade: a model for signal integration 1 Published on the World Wide Web on 22 January 1998. 1 , 1998, Brain Research Reviews.
[6] E. Domino. PCP (phencyclidine), historical and current perspectives , 1981 .
[7] D. Reich,et al. Ketamine: an update on the first twenty-five years of clinical experience , 1989, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[8] D. Lodge,et al. Effects of phencyclidine on excitatory amino acid activation of spinal interneurones in the cat. , 1982, European journal of pharmacology.
[9] M. Giovannini,et al. Glutamatergic regulation of acetylcholine output in different brain regions: A microdialysis study in the rat , 1994, Neurochemistry International.
[10] R. Tandon,et al. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. , 1989, Archives of general psychiatry.
[11] T. Gordh,et al. The NMDA-receptor antagonist CPP abolishes neurogenic ‘wind-up pain’ after intrathecal administration in humans , 1992, Pain.
[12] Tamara Hershey,et al. Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.
[13] G. Rosenbaum,et al. Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.
[14] Dundee Jw,et al. Ketamine-iorazepam. Attenuation of psychic sequelae of ketamine by lorazepam. , 1978 .
[15] P. White,et al. Ketamine--its pharmacology and therapeutic uses. , 1982, Anesthesiology.
[16] F. Mott. ARCHIVES OF NEUROLOGY AND PSYCHIATRY , 1923 .
[17] J. Grotta,et al. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. , 1995, Stroke.
[18] P S Goldman-Rakic,et al. Widespread origin of the primate mesofrontal dopamine system. , 1998, Cerebral cortex.
[19] Herbert Weingartner,et al. NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.
[20] J. Olney,et al. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity , 1996, Schizophrenia Research.
[21] J. Olney,et al. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: Potential relevance to schizophrenia? , 1995, Biological Psychiatry.
[22] O. Bratfos. [Clinical use of benzodiazepines]. , 1977, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[23] J. Olney,et al. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine , 1997, Brain Research.
[24] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[25] Bita Moghaddam,et al. Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.
[26] J. Olney,et al. α2 Adrenergic Agonists Prevent MK-801 Neurotoxicity , 1995, Neuropsychopharmacology.
[27] T. Hicks,et al. Excitatory amino acid transmission , 1987 .
[28] R. Shader,et al. Clinical Uses of Benzodiazepines , 1993, Journal of clinical psychopharmacology.
[29] O. Wolkowitz,et al. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. , 1991, The American journal of psychiatry.
[30] P. Herrling,et al. d-CPPene (SDZ EAA-494)—A Competitive NMDA Antagonist: Pharmacology and Results in Humans , 1997 .
[31] D. Cyril D’Souza,et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans , 1999, Psychopharmacology.
[32] O'Callaghan Jp,et al. Reactive gliosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex: GFAP evaluation by sandwich ELISA and immunocytochemistry. , 1995 .
[33] P S Goldman-Rakic,et al. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[34] B. Moghaddam,et al. Corticolimbic Dopamine Neurotransmission Is Temporally Dissociated from the Cognitive and Locomotor Effects of Phencyclidine , 1998, The Journal of Neuroscience.
[35] R. Tandon,et al. Muscarinic cholinergic hyperactivity in schizophrenia relationship to positive and negative symptoms , 1991, Schizophrenia Research.
[36] K. Lees,et al. Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. , 1997, Clinical neuropharmacology.
[37] J. Olney,et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. , 1999, Science.
[38] G. Buzsáki,et al. MK-801-induced neuronal damage in rats , 1997, Brain Research.
[39] R. Switzer,et al. Dissimilar patterns of degeneration in brain following four different addictive stimulants , 1993, Neuroreport.
[40] J. Olney,et al. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity , 1993, Biological Psychiatry.
[41] J. Olney,et al. NMDA antagonist neurotoxicity: mechanism and prevention. , 1991, Science.
[42] G. Rosenbaum,et al. Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. , 1959, A.M.A. archives of general psychiatry.
[43] J. Olney,et al. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and α2-adrenergic agonists , 1999, Molecular Psychiatry.
[44] R. Buchanan,et al. Diazepam treatment of early signs of exacerbation in schizophrenia. , 1999, The American journal of psychiatry.
[45] G. Rosenbaum,et al. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential thinking. , 1962, Archives of general psychiatry.
[46] P. Goldman-Rakic,et al. Localization of the m2 muscarinic acetylcholine receptor protein and mRNA in cortical neurons of the normal and cholinergically deafferented rhesus monkey , 1998, The Journal of comparative neurology.
[47] J. Magbagbeola,et al. Effect of thiopentone on emergence reactions to ketamine anaesthesia , 1974, Canadian Anaesthetists' Society journal.
[48] J. Olney,et al. Serotonergic Agents That Activate 5HT2A Receptors Prevent NMDA Antagonist Neurotoxicity , 1998, Neuropsychopharmacology.
[49] P. Goldman-Rakic,et al. D1 Receptor in Interneurons of Macaque Prefrontal Cortex: Distribution and Subcellular Localization , 1998, The Journal of Neuroscience.
[50] J. Olney,et al. Halothane prevents MK-801 neurotoxicity in the rat cingulate cortex , 1995, Neuroscience Letters.
[51] J. Olney,et al. Isoflurane and Propofol Block Neurotoxicity Caused by MK-801 in the Rat Posterior Cingulate/Retrosplenial Cortex , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[52] H. Kinoshita,et al. MK-801 increases endogenous acetylcholine release in the rat parietal cortex: a study using brain microdialysis , 1993, Neuroscience Letters.
[53] C. Ikonomidou,et al. Hypobaric-ischemic conditions produce glutamate-like cytopathology in infant rat brain , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[54] J. Olney,et al. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. , 1989, Science.
[55] J. Yesavage,et al. Acute phencyclidine (PCP) intoxication: psychopathology and prognosis. , 1978, The Journal of clinical psychiatry.
[56] R. H. Evans,et al. Excitatory amino acid transmitters. , 1981, Annual review of pharmacology and toxicology.
[57] D. Javitt,et al. Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.
[58] A. Malhotra,et al. Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine , 1997, Biological Psychiatry.
[59] A. Streissguth,et al. Mental illness in adults with fetal alcohol syndrome or fetal alcohol effects. , 1998, The American journal of psychiatry.
[60] J. Olney,et al. Disseminated Corticolimbic Neuronal Degeneration Induced in Rat Brain by MK-801: Potential Relevance to Alzheimer's Disease , 1998, Neurobiology of Disease.
[61] J. Olney,et al. Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.